Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: A prototypical example of biopharmaceutical aggregation

Journal of Pharmaceutical Sciences

Volumn 94, Issue 12, 2005, Pages 2749-2763

  Doyle, Brandon L ^a   Pollo, Mark J ^a   Pekar, Allen H ^a   Roy, Michael L ^a   Thomas, Beth Ann ^a   Brader, Mark L ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Aggregation; Circular; Dichroism; Fluorescence spectroscopy; FTIR; Light scattering; Peptides; Physical stability

Indexed keywords

ACETONITRILE; AMINO ACID; DYE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LY 307161; MONOMER;

ALPHA HELIX; ARTICLE; BETA SHEET; BIOPHYSICS; CIRCULAR DICHROISM; COMPARATIVE STUDY; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); COVALENT BOND; DRUG SOLUTION; FLUORESCENCE SPECTROSCOPY; FREEZE DRYING; INFRARED SPECTROSCOPY; LIGHT SCATTERING; PH; PHYSICAL CHEMISTRY; POWDER; PRECIPITATION; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN STABILITY; SEDIMENTATION; SOLID STATE; SOLUBILITY;

EID: 33144465205     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20420     Document Type: Article

References (30)

1. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. 1992. Antidiabetogenic effect of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322.
2. Drucker DJ. 2001. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 14:1399-1412.
3. Kim Y, Rose CA, Liu Y, Ozaki Y, Datta G, Tu AT. 1994. FT-IR and Near-infrared FT-Raman studies of the secondary structure of insulinotropin in the solid state: α-helix to β-sheet conversion induced by phenol and/or by high shear force. J Pharm Sci 83:1175-1180.
4. Senderoff RI, Kontor KM, Kreilgaard L, Chang JJ, Patel S, Krakover J, Heffernan JK, Snell LB, Rosenberg GB. 1998. Consideration of conformational transitions and racemization during process development of recombinant glucagon-like peptide-1. J Pharm Sci 87:183-189.
5. Porter S. 2001. Human immune response to recombinant human proteins. J Pharm Sci 90:1-11.
6. Schellekens H, Casadevall N. 2004. Immunogenicity of recombinant human proteins: Causes and consequences. J Neurol 251:11/4-11/9.
7. Clodfelter DK, Pekar AH, Rebhun DM, Destrampe KA, Havel HA, Myers SR, Brader ML. 1998. Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide. Pharm Res 15:254-262.
8. Carpenter JF, Manning MC. 2002. Rational design of stable protein formulations: Theory and practice. Kluwer Academic/Plenum Publishers.
9. Volkin DB, Mach H, Middaugh CR. 1995. Degradative covalent reactions important to protein stability. In: Shirley BA, editor. Protein stability and folding. Totowa: Humana Press Inc., pp 35-63.
10. Wang W. 1999. Instability, stabilization and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188.
11. Wen J, Arakawa T, Philo JS. 1996. Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Anal Biochem 240:155-166.
12. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt K, Macdougall IC. 2004. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. The Lancet 363:1768-1771.
13. Hermeling S, Schellekens H, Crommelin DJA, Jiskroot W. 2003. Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity? Pharm Res 20:1903-1907.
14. Chirino AJ, Ary ML, Marshall SA. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9:82-90.
15. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24:1720-1740.
16. Schellekens H. 2004. When biotech proteins go off-patent. Trends in Biotechnology 22:406-410.
17. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93:1390-1402.
18. Chirino AJ, Mire-Sluis A. 2004. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22:1383-1391.
19. Laue TM, Shah B, Ridgeway TM, Pelletier SL. 1992. Computer-aided interpretation of analytical sedimentation data for proteins. In: Harding SE, Rowe AJ, Horton JC, editors. Analytical ultracentrifugation in biochemistry and polymer science. Cambridge, UK: The Royal Society of Chemistry, pp 90-125.
20. Meyer JD, Manning MC, Carpenter JF. 2004. Effects of potassium bromide disk formation on the infrared spectra of dried model proteins. J Pharm Sci 93:496-506.
21. Haris PI. 2000. Fourier transform infrared spectroscopic studies of peptides: Potentials and pitfalls. In: Singh BR, editor. Infrared analysis of peptides and proteins Principles and applications. Washington, DC: American Chemical Society, 70p 54-95.
22. Dong A, Prestrelski SJ, Allison SD, Carpenter JF. 1995. Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. J Pharm Sci 84:415-424.
23. Nielsen L, Frokjaer S, Carpenter JF, Brange J. 2001. Studies of the structure of insulin fibrils by Fourier Transform Infrared (FTIR) Spectroscopy and Electron Microscopy. J Pharm Sci 90:29-37.
24. Ladokhin AS. 2000. Fluorescence spectroscopy in peptide and protein analysis. In: Meyers RA, editor. Encyclopedia of Analytical Chemistry. Chichester: John Wiley and Sons Ltd., pp 5762-5779.
25. LeVine HD. 1993. Thioflavin T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Science 2:404-410.
26. Klunk WE, Jacob RF, Mason RP. 1999. Quantifying amyloid β-peptide (Aβ) aggregation using the congo red-Aβ (CR-Aβ) spectrophotometric assay. Anal Biochem 266:66-76.
27. Patapoff TW, Mrsny RJ, Lee WA. 1993. The application of size exclusion chromatography and computer simulation to study the thermodynamic and kinetic parameters for short-lived dissociable protein aggregates. Anal Biochem 212:71-78.
28. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O. 1994. Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269:6275-6278.
29. Andersen NH, Brodsky Y, Neidigh JW, Prickett KS. 2002. Medium-dependence of the secondary structure of Exendin-4 and glucagon-like peptide-1. Bioorg Med Chem 10:79-85.
30. Thornton K, Gorenstein DG. 1994. Structure of glucagon-like peptide(7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 33:3532-3539.